Business Context and Reporting Period
This Form 8-K, dated September 19, 2025, reports on Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a Delaware corporation. The filing details the entry into a Material Definitive Agreement for a private placement offering. While the request metadata references "Aixcrypto Holdings, Inc.", the filing text explicitly identifies the registrant as Qualigen Therapeutics, Inc., which intends to establish cryptocurrency treasury operations using the proceeds.
Key Financial Metrics and Transaction Details
- Offering Size: $41,000,000 in cash proceeds.
- Securities Issued: Common Stock and Series B Convertible Preferred Stock.
- Purchase Prices: Common Stock at $2.246 per share; Series B Stock at $1,000 Stated Value per share.
- Use of Proceeds: Up to $6,800,000 for existing debt repayment and operations; the balance for cryptocurrency treasury operations.
- Placement Agent Fees: 5.5% cash fee of gross proceeds plus warrants for 6% of securities sold (exercise price $2.47).
- Advisory Compensation: Approximately 60,257 shares of Common Stock (5% of post-closing outstanding).
- Debt and Liquidity: The filing does not provide current total debt, cash balance, or liquidity metrics prior to this transaction.
Material Changes and Corporate Actions
- Capital Structure: Introduction of Series B Convertible Preferred Stock with a conversion price of $2.246, convertible only after stockholder approval.
- Board Composition: Reduction of the Board to five members, including the resignation of Cody Price, Campbell Becher, and Robert Lim. Two designees of the Lead Investor (Faraday Future Intelligent Electric Inc.) will be appointed.
- Executive Leadership: Appointment of Jiawei Wang as Co-Chief Executive Officer and Koti Meka as Chief Financial Officer.
- Ownership Caps: An "Exchange Cap" limits any single purchaser's ownership of Common Stock to 19.99% of shares outstanding.
Guidance, Risks, and Contingencies
- Stockholder Approval Requirement: Conversion of Series B Stock is contingent on stockholder approval (via written consent or special meeting) by October 29, 2025 (potentially November 28, 2025 if reviewed by the SEC). If not obtained, the company must hold meetings every 90 days until approval is secured.
- Registration Rights: The company must file a resale registration statement within 45 days of closing and seek effectiveness within 45 days thereafter.
- Closing Conditions: The closing is expected on or about September 29, 2025, subject to customary conditions.
- Lead Investor Rights: Faraday Future Intelligent Electric Inc. holds rights to appoint directors proportional to ownership (if >5%), participate in subsequent financings, and receive observer status if ownership drops below the threshold.
Investor Verification Checklist
- Verify the exact allocation of the $41,000,000 between Common Stock and Series B Stock.
- Confirm the timeline and outcome of the required stockholder vote for Series B conversion.
- Review the full Certificate of Designation for Series B Stock to understand liquidation preferences and dividend rights.
- Assess the impact of the new Co-CEO and CFO appointments on strategic direction.
- Monitor the filing of the resale registration statement within the mandated 45-day window.